Current Issues Regarding the use of Adaptive Designs in Clinical Trials

<table>
<thead>
<tr>
<th>Current Issues</th>
<th>PRESENTERS</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m. – 8:30 a.m.</td>
<td>BREAKFAST</td>
</tr>
</tbody>
</table>
| 8:30 a.m. – 8:40 a.m. | Opening Remarks and Logistics  
Jonathan A. Epstein MD, University of Pennsylvania |
| 8:40 a.m. – 9:05 a.m. | Moderator: Andrea Troxel, University of Pennsylvania  
Adaptive Designs: The Swiss Army Knife Among Clinical Trial Designs? |
| 9:05 a.m. – 9:30 a.m. | Michael Proschan, PhD, NIAID  
Blinded Adaptations: What Is and Is Not Okay? |
| 9:30 a.m. – 9:55 a.m. | Peter F. Thall, PhD, MD Anderson Cancer Center  
Caveats for Outcome-Adaptive Randomization in Comparative Clinical Trials |
| 9:55 a.m. – 10:20 a.m. | BREAK |
| 10:20 a.m. – 11:15 a.m. | Discussion panel:  
Valerie Durkalski, PhD, Medical University of South Carolina  
Steven Joffe, MD, MPH, University of Pennsylvania  
Rick Chappell, PhD, University of Wisconsin-Madison |
| 11:15 a.m. – 11:35 a.m. | OPEN FORUM |
| 11:35 a.m. – 12:55 p.m. | LUNCH |
| 12:55 p.m. – 1:20 p.m. | Mahesh Parmar, DPhil, University College London  
Improving Outcomes for Patients As Rapidly As Possible: Some New Designs for Phase III Trials |
| 1:20 p.m. – 1:45 p.m. | Bruce W. Turnbull, PhD, Cornell University  
Adaptive Trial Designs: A DSMB Perspective |
| 1:45 p.m. – 2:10 p.m. | Lisa LaVange, PhD, FDA  
Adaptive Trial Designs and the FDA |
| 2:10 p.m. – 2:35 p.m. | BREAK |
| 2:35 p.m. – 3:25 p.m. | Discussion panel:  
Janet Wittes, PhD, Statistics Collaborative, Inc.  
Angie DeMichele, MD, MSCE, University of Pennsylvania  
Jason T. Connor, PhD, Berry Consultants |
| 3:25 p.m. – 3:45 p.m. | OPEN FORUM |
| 3:45 p.m. – 4:00 p.m. | CLOSING REMARKS: Susan Ellenberg, University of Pennsylvania |